Apolipoprotein E Genotypes as Predictors of High-Risk Groups for Developing Hyperlipidemia in Kidney Transplant Recipients Undergoing Sirolimus Treatment
Authors:
- Daniel G. MalufDMDaniel G. Maluf
- Valeria R. MasVMValeria R. Mas
- Kellie J. ArcherKAKellie J. Archer
- Kenneth YanekKYKenneth Yanek
- Anne KingAKAnne King
- Andrea Ferreira-GonzalezAFAndrea Ferreira-Gonzalez
- Robert A. FisherRFRobert A. Fisher
- Marc PosnerMPMarc Posner
- 27 December 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 80 (12) , 1705-1711
Abstract
Hypercholesterolemia (HCHL) and hypertriglyceridemia (HTRG) have emerged as the most significant metabolic consequences of therapy with sirolimus. Lipid status can be exacerbated by a variety of factors in the posttransplant setting, including genetic factors. Apoliprotein E (Apo E) polymorphism is an established genetic risk factor for hyperlipidemia. We studied the association between Apo E gene polymorphisms and lipids after kidney transplantation in patients undergoing sirolimus treatment. We studied 98 kidney transplant patients (KTP) with stable renal allograft undergoing sirolimus treatment: 39 with HCHL and HTRG within 90 days postsirolimus treatment (PST) and 59 without hyperlipidemia PST. Apo E genotyping was performed using INNO-LiPA-ApoE. The cholesterol and the triglyceride values between the groups were 323.3±71.6 vs. 180.9±31.2 mg/dL (P<0.001) and 318.9±97.2 vs. 159.7±38.7 mg/dL (P<0.001). There was a significant difference in the genotype distribution of the hyperlipidemia and normal groups (P=0.009) with the percentages in each group as follows: E2/2 and E3/2: 12.8 vs. 5.1%; E3/3: 69.2% vs. 86.4%; and E4/3 and E4/4: 18.0% vs. 8.5%. We observed a higher number of patients with the genotype E3/3 in the group without hyperlipidemia PST (P=0.039). E3/2 and E4/4 genotype frequencies were higher in patients with hyperlipidemia PST. LDL levels in the hyperlipidemia PST group was statistical significant higher (P<0.001) and we observed an association between Apo E allelic distribution and LDL (P=0.005). Genetic factors, as Apo E genotypes, could allow the early identification of patients who are at a high risk for developing hyperlipidemia PST.Keywords
This publication has 40 references indexed in Scilit:
- Genetic Basis of Atherosclerosis: Part ICirculation, 2004
- Apolipoprotein E gene polymorphism in renal transplant recipients: effects on lipid metabolism, atherosclerosis and allograft functionClinical Transplantation, 2004
- Immune and Nonimmune Predictors of Cardiac Allograft Vasculopathy Onset and Severity: Multivariate Risk Factor Analysis and Role of ImmunosuppressionAmerican Journal of Transplantation, 2004
- Effect of Immunosuppressive Agents on Long-Term Survival of Renal Transplant RecipientsDrugs, 2004
- Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine–based immunosuppressive regimen: incidence, risk factors, progression, and prognosis1Transplantation, 2003
- THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Traditional Cardiac Risk Factors in Individuals with Chronic Kidney DiseaseSeminars in Dialysis, 2003
- Apolipoprotein E gene polymorphism alters lipids before pancreas transplantationTransplantation, 2002
- SIROLIMUS (RAPAMYCIN)-BASED THERAPY IN HUMAN RENAL TRANSPLANTATIONTransplantation, 1999
- HYPERLIPIDEMIA IN RENAL TRANSPLANT RECIPIENTS TREATED WITH SIROLIMUS(RAPAMYCIN)Transplantation, 1998
- A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulinAtherosclerosis, 1997